Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats

Vascular Pharmacology

Volumn 46, Issue 3, 2007, Pages 188-194

  Desouza, Cyrus V ^a,b   Gerety, Moira ^a,b   Hamel, Frederick G ^a,b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Endothelial regrowth; Insulin resistance; Neointimal hyperplasia; Pioglitazone; PPAR gamma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPERINSULINEMIA; INSULIN RESISTANCE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; FEMALE; HYPERPLASIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PPAR GAMMA; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; TUNICA INTIMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846257288     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.10.001     Document Type: Article

References (53)

1. Aizawa Y., Kawabe J., Hasebe N., Takehara N., and Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104 (2001) 455-460
2. Asahara T., Bauters C., Pastore C., Kearney M., Rossow S., Bunting S., Ferrara N., Symes J.F., and Isner J.M. Local delivery of Vascular Endothelial Growth Factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91 (1995) 2793-2801
3. Asahara T., Chen D., Tsurumi Y., Kearney M., Rossow S., Passeri J., Symes J.F., and Isner J.M. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94 (1996) 3291-3302
4. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129 (2000) 823-834
5. Callow A.D., Choi E.T., Trachtenberg J.D., Stevens S.L., Connolly D.T., Rodi C., and Ryan U.S. Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty. Growth Factors 10 (1994) 223-228
6. Clowes A.W., Clowes M.M., and Reidy M.A. Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. Lab. Invest. 54 (1986) 295-303
7. Concina P., Sordello S., Barbacanne M.A., Elhage R., Pieraggi M.T., Fournial G., Plouet J., Bayard F., and Arnal J.F. The mitogenic effect of 17beta-estradiol on in vitro endothelial cell proliferation and on in vivo reendothelialization are both dependent on Vascular Endothelial Growth Factor. J. Vasc. Res. 37 (2000) 202-208
8. Desouza C.V., Murthy S.N., Diez J., Dunne B., Matta A.S., Fonseca V.A., and McNamara D.B. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J. Cardiovasc. Pharmacol. Ther. 8 (2003) 297-305
9. Desouza C.M.S., Diez J., Fonseca V., and McNamara D.B. Effect of peroxisome proliferator activator receptor ligands on intimal hyperplasia after balloon catheter induced vascular injury in ZDF diabetic rats. J. Cardiovasc. Pharmacol. Ther. (2003)
10. Desouza C.V., Gerety M., and Hamel F.G. Neointimal hyperplasia and Vascular Endothelial Growth Factor expression are increased in normoglycemic, insulin resistant, obese fatty rats. Atherosclerosis 184 (2006) 283-289
11. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
12. Dulak J., Jozkowicz A., Dichtl W., Alber H., Schwarzacher S.P., Pachinger O., Weidinger F., and Dulakk J. Vascular Endothelial Growth Factor synthesis in vascular smooth muscle cells is enhanced by 7-ketocholesterol and lysophosphatidylcholine independently of their effect on nitric oxide generation. Atherosclerosis 159 (2001) 325-332
13. Fonseca V., Desouza C., Asnani S., and Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr. Rev. 25 (2004) 153-175
14. Fukunaga Y., Itoh H., Doi K., Tanaka T., Yamashita J., Chun T.H., Inoue M., Masatsugu K., Sawada N., Saito T., Hosoda K., Kook H., Ueda M., and Nakao K. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158 (2001) 113-119
15. Golden S.H., Folsom A.R., Coresh J., Sharrett A.R., Szklo M., and Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51 (2002) 3069-3076
16. Gonzalez-Fernandez F., Lopez-Farre A., Rodriguez-Feo J.A., Farre J., Guerra J., Fortes J., Millas I., Garcia-Duran M., Rico L., Mata P., de Miguel L.S., and Casado S. Expression of inducible nitric oxide synthase after endothelial denudation of the rat carotid artery: role of platelets. Circ. Res. 83 (1998) 1080-1087
17. Groves P.H., Banning A.P., Penny W.J., Lewis M.J., Cheadle H.A., and Newby A.C. Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury. Atherosclerosis 117 (1995) 83-96
18. Haffner S.M., Mykkanen L., Festa A., Burke J.P., and Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101 (2000) 975-980
19. Hedblad B., Nilsson P., Engstrom G., Berglund G., and Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet. Med. 19 (2002) 470-475
20. Hsueh W.A., and Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1891-1895
21. Hsueh W.A., Jackson S., and Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24 (2001) 392-397
22. Igarashi M., Takeda Y., Ishibashi N., Takahashi K., Mori S., Tominaga M., and Saito Y. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm. Metab. Res. 29 (1997) 444-449
23. Igarashi M., Hirata A., Yamaguchi H., Tsuchiya H., Ohnuma H., Tominaga M., Daimon M., and Kato T. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 50 (2001) 955-962
24. Indolfi C., Torella D., Coppola C., Stabile E., Esposito G., Curcio A., Pisani A., Cavuto L., Arcucci O., Cireddu M., Troncone G., and Chiariello M. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H760-H767
25. Kareinen A., Viitanen L., Halonen P., Lehto S., and Laakso M. Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1346-1352
26. Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., and Watanabe T. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem. Biophys. Res. Commun. 258 (1999) 431-435
27. Lafont A., Durand E., Samuel J.L., Besse B., Addad F., Levy B.I., Desnos M., Guerot C., and Boulanger C.M. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 100 (1999) 1109-1115
28. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., and Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101 (2000) 1311-1318
29. Meigs J.B. Epidemiology of the metabolic syndrome. Am. J. Manag. Care 8 (2002) S283-S292 (quiz S293-286)
30. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
31. Onat A., Ceyhan K., Sansoy V., Basar O., Erer B., Uysal O., and Hergenc G. Fasting insulin levels independently associated with coronary heart disease in non-diabetic Turkish men and women. Int. J. Cardiol. 86 (2002) 61
32. Park S.H., Marso S.P., Zhou Z., Foroudi F., Topol E.J., and Lincoff A.M. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104 (2001) 815-819
33. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
34. Picard P., Smith P.J., Monge J.C., and Stewart D.J. Expression of endothelial factors after arterial injury in the rat. J. Cardiovasc. Pharmacol. 31 Suppl 1 (1998) S323-S327
35. Poppa V., Miyashiro J.K., Corson M.A., and Berk B.C. Endothelial NO synthase is increased in regenerating endothelium after denuding injury of the rat aorta. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1312-1321
36. Pyorala M., Miettinen H., Halonen P., Laakso M., and Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 538-544
37. Ratner M. Genentech discloses safety concerns over Avastin. Nat. Biotechnol. 22 (2004) 1198
38. Reidy M.A. Endothelial regeneration. VIII. Interaction of smooth muscle cells with endothelial regrowth. Lab. Invest. 59 (1988) 36-43
39. Romano Di Peppe S., Mangoni A., Zambruno G., Spinetti G., Melillo G., Napolitano M., and Capogrossi M.C. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther. 9 (2002) 1271-1277
40. Schiller N.K., Timothy A.M., Chen I.L., Rice J.C., Akers D.L., Kadowitz P.J., and McNamara D.B. Endothelial cell regrowth and morphology after balloon catheter injury of alloxan-induced diabetic rabbits. Am. J. Physiol. 277 (1999) H740-H748
41. Spaet T.H., Stemerman M.B., Veith F.J., and Lejnieks I. Intimal injury and regrowth in the rabbit aorta; medial smooth muscle cells as a source of neointima. Circ. Res. 36 (1975) 58-70
42. Tada T., and Reidy M.A. Endothelial regeneration. IX. Arterial injury followed by rapid endothelial repair induces smooth-muscle-cell proliferation but not intimal thickening. Am. J. Pathol. 129 (1987) 429-433
43. Takagi T., Yoshida K., Akasaka T., Kaji S., Kawamoto T., Honda Y., Yamamuro A., Hozumi T., and Morioka S. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J. Am. Coll. Cardiol. 36 (2000) 731-738
44. Takagi T., Akasaka T., Yamamuro A., Honda Y., Hozumi T., Morioka S., and Yoshida K. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies. J. Diabetes Complicat. 16 (2002) 50-55
45. Tontonoz P., and Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr. Opin. Lipidol. 10 (1999) 485-490
46. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
47. Tsuchihashi K., Hikita N., Hase M., Agata J., Saitoh S., Nakata T., Ura N., and Shimamoto K. Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi-quantitative coronary angiography. Intern. Med. 38 (1999) 691-697
48. Visweswaran P., Johnson A.D., Tock C.L., Engler D.A., Schwarz J.J., Casscells S.W., and Scott-Burden T. Stimulation of growth and migration of vascular endothelial cells by Vascular Endothelial Growth Factor transduced smooth muscle cells in co-culture. ASAIO J. 43 (1997) M753-M758
49. Wagenknecht L.E., D'Agostino Jr. R.B., Haffner S.M., Savage P.J., and Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care 21 (1998) 1812-1818
50. Walker A.B., Chattington P.D., Buckingham R.E., and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 (1999) 1448-1453
51. Wang Z., Castresana M.R., and Newman W.H. Reactive oxygen and NF-kappaB in VEGF-induced migration of human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 285 (2001) 669-674
52. Watanabe Y., Sunayama S., Shimada K., Sawano M., Hoshi S., Iwama Y., Mokuno H., Daida H., and Yamaguchi H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J. Atheroscler. Thromb. 7 (2000) 159-163
53. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., and Nishizawa Y. Peroxisome proliferator-activated receptor-gamma agonists increase Vascular Endothelial Growth Factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271 (2000) 571-574